Opportunity PA-06-361

The summary for the Opportunity PA-06-361 grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Opportunity PA-06-361: The purpose of this funding opportunity announcement (FOA) is to stimulate multidisciplinary research on potential reduced-exposure tobacco products, both smoked and smokeless, through the interplay of basic, biological, behavioral, surveillance, and epidemiology research. The tobacco industry is currently promoting some new products with claims that they are less harmful or less addictive because these products purportedly deliver lower amounts of toxic, carcinogenic, and/or addictive agents to the user compared with conventional products. However, to date, the scientific evidence is insufficient to evaluate whether these new products actually reduce the users exposure or risk for tobacco-related diseases. The key research question of this FOA is, Do potential reduced-exposure tobacco products provide a truly, less-harmful alternative to conventional tobacco products, both on the individual and population level? -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. -This FOA utilizes the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-04-103, which is now a solicitation for applications using the NIH Research Project Grant (R01) mechanism only. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations include: for-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of local governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; and faith-based or community-based organizations; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); and Indian/Native American Tribally Designated Organization. -Eligible Project Directors/Principal Investigators (PDs/PIs) include any individual from the institution with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.
Federal Grant Title: Opportunity PA-06-361
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-06-361
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: May 07, 2009 Mult
Original Application Deadline: Feb 19, 2009 Multi
Posted Date: Apr 18, 2006
Creation Date: Mar 16, 2009
Archive Date: Jun 07, 2009
Total Program Funding:
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply. -Faith-based or community-based organizations; -Indian/Native American Tribal Government (Federally Recognized); -Indian/Native American Tribal Government (Other than Federally Recognized); -Indian/Native American Tribally Designated Organization.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com